Loading clinical trials...
Loading clinical trials...
A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
Conditions
Interventions
Revlimid
Locations
7
France
Centre Hospitalier de la côte basque
Bayonne, France
Ch Clermond Ferrand
Clermont-Ferrand, France
CH LENS
Lens, France
Chru Lille
Lille, France
Ch Nantes
Nantes, France
Groupe hospitalier Pitié Salpétrière
Paris, France
Start Date
March 1, 2009
Primary Completion Date
March 1, 2017
Completion Date
April 1, 2017
Last Updated
November 28, 2025
NCT07387471
NCT06510491
NCT01804686
NCT02269592
NCT05602363
NCT07231952
Lead Sponsor
University Hospital, Lille
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions